Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2019 to Jul 2024
GammaCan International, Inc. (OTC BB: GCAN), a developer of
immunotherapies for the treatment of cancer and other diseases, today
announced that Patrick Schnegelsberg, Chief Executive Officer, is
scheduled to present VitiGam, GammaCan's second generation product under
development for the treatment of melanoma, to the investor,
biotechnology and pharma community at the BioPartnering Europe
Conference.
The conference will be held at the Queen Elizabeth II Conference Centre
in London from October 8-11, 2006. Mr. Schnegelsberg is scheduled to
present on Monday, October 9th at 12 Noon GMT.
About VitiGam:
VitiGam is GammaCan's second generation intravenous IgG-based product
and a first-in-class anti-cancer immunotherapy. GammaCan plans on having
VitiGam to enter phase I/II testing under a US IND in the near future
after it recently held a pre-IND meeting with the FDA. VitiGam is being
designed to target metastatic melanoma patients with Stage III and IV
melanoma. VitiGam is an IgG product that is different from standard
IgGs: It is manufactured from the plasma of donors with vitiligo, a
benign autoimmune skin condition affecting up to 2% of the general
population. GammaCan scientists have shown that this "enriched" vitiligo
IgG (VitiGam) contains potent anti-melanoma activity in both in vitro
and mouse xenograft melanoma models. Thus, GammaCan expects VitiGam to
provide (1) anti-melanoma activity directed specifically against
malignant melanoma cells and (2) non-specific anti-cancer activity - as
is the case with IgG in general.
About GammaCan
GammaCan is focusing on the commercialization of an innovative
anti-cancer immunotherapy to treat metastatic cancer. GammaCan's
platform is based on IgG, a safe, relatively non-toxic human
plasma-based product, currently used to treat a variety of immune
deficiencies and autoimmune diseases. IgG works by strengthening the
patient's immune system. Many experts currently view immunotherapy as a
future alternative to today's standard chemotherapy. GammaCan is
developing VitiGam, its second generation program. VitiGam is an IgG
derived from the plasma of vitiligo donors and is being developed to
treat malignant melanoma. GammaCan owns, and has applied for US patent
protection covering the use of IgG and vitiligo-derived IgG (VitiGam).
For more information about GammaCan visit www.GammaCan.com
or call the company's headquarters in Kiryat Ono, Israel at +972 (03)
738-2616 or toll free 1-866-308-0396 (from North America).
Safe Harbor Statement:
Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this release
include statements regarding the commercialization of an anti-cancer
immunotherapy and the Company developing the boosting of cancer
patients' immune systems with IgG into an effective treatment. Actual
outcomes and the Company's actual results could differ materially from
those in such forward-looking statements. Factors that could cause
actual results to differ materially include risks and uncertainties such
as the inability to finance the planned development of the technology,
unforeseen technical difficulties in developing the technology, the
inability to obtain regulatory approval for human use, competitors'
therapies proving more effective, cheaper or otherwise preferable for
consumers, inability to market the product we produce, among other
factors, all of which could among other things, delay or prevent product
release or cause our company to fail. For further risk factors see the
risk factors associated with other early state medical research and
development companies filed with the SEC on Edgar.
GammaCan International, Inc. (OTC BB: GCAN), a developer of
immunotherapies for the treatment of cancer and other diseases, today
announced that Patrick Schnegelsberg, Chief Executive Officer, is
scheduled to present VitiGam, GammaCan's second generation product
under development for the treatment of melanoma, to the investor,
biotechnology and pharma community at the BioPartnering Europe
Conference.
The conference will be held at the Queen Elizabeth II Conference
Centre in London from October 8-11, 2006. Mr. Schnegelsberg is
scheduled to present on Monday, October 9th at 12 Noon GMT.
About VitiGam:
VitiGam is GammaCan's second generation intravenous IgG-based
product and a first-in-class anti-cancer immunotherapy. GammaCan plans
on having VitiGam to enter phase I/II testing under a US IND in the
near future after it recently held a pre-IND meeting with the FDA.
VitiGam is being designed to target metastatic melanoma patients with
Stage III and IV melanoma. VitiGam is an IgG product that is different
from standard IgGs: It is manufactured from the plasma of donors with
vitiligo, a benign autoimmune skin condition affecting up to 2% of the
general population. GammaCan scientists have shown that this
"enriched" vitiligo IgG (VitiGam) contains potent anti-melanoma
activity in both in vitro and mouse xenograft melanoma models. Thus,
GammaCan expects VitiGam to provide (1) anti-melanoma activity
directed specifically against malignant melanoma cells and (2)
non-specific anti-cancer activity - as is the case with IgG in
general.
About GammaCan
GammaCan is focusing on the commercialization of an innovative
anti-cancer immunotherapy to treat metastatic cancer. GammaCan's
platform is based on IgG, a safe, relatively non-toxic human
plasma-based product, currently used to treat a variety of immune
deficiencies and autoimmune diseases. IgG works by strengthening the
patient's immune system. Many experts currently view immunotherapy as
a future alternative to today's standard chemotherapy. GammaCan is
developing VitiGam, its second generation program. VitiGam is an IgG
derived from the plasma of vitiligo donors and is being developed to
treat malignant melanoma. GammaCan owns, and has applied for US patent
protection covering the use of IgG and vitiligo-derived IgG (VitiGam).
For more information about GammaCan visit www.GammaCan.com or call
the company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616
or toll free 1-866-308-0396 (from North America).
Safe Harbor Statement:
Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this release
include statements regarding the commercialization of an anti-cancer
immunotherapy and the Company developing the boosting of cancer
patients' immune systems with IgG into an effective treatment. Actual
outcomes and the Company's actual results could differ materially from
those in such forward-looking statements. Factors that could cause
actual results to differ materially include risks and uncertainties
such as the inability to finance the planned development of the
technology, unforeseen technical difficulties in developing the
technology, the inability to obtain regulatory approval for human use,
competitors' therapies proving more effective, cheaper or otherwise
preferable for consumers, inability to market the product we produce,
among other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further risk
factors see the risk factors associated with other early state medical
research and development companies filed with the SEC on Edgar.